[1] Lu W, Qu J, Yan L, et al.Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis. Stem Cell Res Ther, 2023, 14(1):301. [2] Pose E, Piano S, Juanola A, et al. Hepatorenal syndrome in cirrhosis. Gastroenterology, 2024,166(4):588-604,e1. [3] Rose CF, Amodio P, Bajaj JS, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol, 2020, 73(6): 1526-1547. [4] 姚俞昊, 张嘉鑫, 夏潇, 等. 益生菌对轻微型肝性脑病患者HE发生率影响的Meta分析. 临床肝胆病杂志, 2022, 38(11): 2505-2509. [5] Cho MR, Lee S, Song SK. A review of sarcopenia pathophysiology, diagnosis, treatment and future direction. J Korean Med Sci, 2022, 37(18): 146. [6] Coelho MPP, de Castro PASV, de Vries TP, et al. Sarcopenia in chronic viral hepatitis: from concept to clinical relevance. World J Hepatol, 2023, 15(5): 649-665. [7] Rodge GA, Goenka U, Jajodia S, et al. Psoas muscle index: a simple and reliable method of sarcopenia assessment on computed tomography scan in chronic liver disease and its impact on mortality. J Clin Exp Hepatol, 2023, 13(2): 196-202. [8] Nishikawa H, Enomoto H, Nishiguchi S, et al. Liver cirrhosis and sarcopenia from the viewpoint of dysbiosis. Int J Mol Sci, 2020, 21(15): 5254. [9] González-Regueiro JA, Higuera-de la Tijera MF, Moreno-Alcántar R, et al. Pathophysiology of hepatic encephalopathy and future treatment options. Rev Gastroenterol Mex (Engl Ed), 2019, 84(2): 195-203. [10] 中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版). 中华外科杂志, 2019, 57(12):885-892. [11] Rahimi RS, Brown KA, Flamm SL, et al. Overt hepatic encephalopathy: current pharmacologic treatments and improving clinical outcomes. Am J Med, 2021, 134(11): 1330-1338. [12] Ridola L, Faccioli J, Nardelli S, et al. Hepatic encephalopathy: diagnosis and management. J Transl Int Med, 2020, 8(4): 210-219. [13] Moran S, López-Sánchez M, Milke-García MDP, et al. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. World J Gastroenterol, 2021, 27(22): 3050-3063. [14] Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol, 2019, 31(4): 434-450. [15] Nardelli S, Gioia S, Faccioli J, et al. Hepatic encephalopathy - recent advances in treatment and diagnosis. Expert Rev Gastroenterol Hepatol, 2023, 17(3): 225-235. [16] Sweeney E, Richardson P. Overt hepatic encephalopathy: management and prevention of recurrence. Br J Nurs, 2020, 29(17): 14-17. [17] Liu J, Zhou C, Wang Y, et al. The combination of Child-Pugh score and quantitative CT-based spleen volume could predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation. Abdom Radiol (NY), 2021, 46(7): 3464-3470. [18] Yokoyama K, Fukuda H, Yamauchi R, et al. Long-term effects of rifaximin on patients with hepatic encephalopathy: its possible effects on the improvement in the blood ammonia concentration levels, hepatic spare ability and refractory ascites. Medicina (Kaunas), 2022, 58(9): 1276. [19] Wang K, Long W, Sima X, et al. Sarcopenia defined by skeletal muscle mass index at the third lumbar vertebra is a prognostic factor for extensive-stage small cell lung cancer patients: a retrospective study. J Thorac Dis, 2022, 14(7): 2645-2651. [20] Tapper EB, Parikh ND.Diagnosis and management of cirrhosis and its complications: A review. JAMA, 2023,329(18):1589-1602. |